• Journal of Physiology & Pathology in Korean Medicine
• /
• v.33 no.4
• /
• pp.239-248
• /
• 2019

There are no published data on Gyeongokgo (GOK) safety or efficacy despite being commonly use. The Gyeongokgo (GOK) is commonly used in traditional Korean medicine to promote a health qi and blood, but their objective data was not sufficient in clinical field. To investigate the safety and efficacy of GOK with hematologic and serologic testing and the change of the quality of life in healthy individuals. Randomized, subject-assessor-blind, placebo-controlled, single-center pilot study Participants and Interventions 29 healthy volunteer subjects were randomly placed into the GOK group (n = 20) or placebo control group (n = 9) and instructed to take one treatment packet (GOK or placebo) twice daily for 4 weeks. Subjects were assessed using the Fatigue Severity Scale (FSS) and Short Form 36 Health Survey (SF-36) and underwent hematologic and serologic tests and body composition analysis. The FSS total score (p = 0.093) and SF-36 general health index (p = 0.002) were improved following treatment in the GOK group. Post-treatment thyroid-stimulating hormone levels were increased in the GOK group compared with pre-treatment levels (p = 0.0042). C-reactive protein levels decreased (p = 0.0256) in the GOK group compared with that the placebo group. In time-series tests, GOK did not affect post-prandial serum triglycerides, glucose, insulin, or C-peptide levels. Notably, elevations in serum fasting triglycerides at 2- (p = 0.0333) and 4-hours (p = 0.0414) post-prandial were lower than those in the placebo group. GOK reduced fatigue levels and did not significantly affect laboratory test results performed to measure safety, serum glucose, and lipid profiles. Post-meal triglyceride levels were effectively reduced with treatment.

• Journal of agricultural medicine and community health
• /
• v.42 no.4
• /
• pp.215-225
• /
• 2017

• The Journal of Korean Obstetrics and Gynecology
• /
• v.24 no.3
• /
• pp.127-145
• /
• 2011

Purpose: The purpose of this study is to analyze the effect of oriental-western medicine integrative care after gynecology surgery by DSOM((Diagnosis System of Oriental Medicine) and improvement of major symptoms. Methods: 66 patients belonged to the experimental group and 47 patients belonged to the control group out of 113 patients taken gynecology surgery. We studied general characteristics and difference on DSOM results between the two groups. And we had patients answer questionnaires about major symptoms such as abdominal discomfort, headache, fatigue, urinary discomfort, constipation, lumbago, edema, tingling, digestive disorder, cough, pruritus, arthralgia, cold feeling by VAS (Visual Analogue Scale) in order to analyze improvement and difference between two groups. Results: Experimental group had significantly high score on deficiency of blood, blood stasis, dryness, spleen, kidney, phlegm and high frequency on deficiency of blood, dampness, kidney, phlegm pathogenesis in DSOM. It had significantly high intensity in symptoms of abdominal discomfort, headache, fatigue, urinary discomfort, constipation, lumbago at the first time, and headache at 1 month after western hospital discharge out of symptoms associated with surgery. And it had significantly high improvement in symptoms of abdominal discomfort, headache, urinary discomfort, constipation at oriental-western integrative hospital discharge, and headache, fatigue, urinary discomfort, constipation, lumbago at 1 month after western hospital discharge out of symptoms associated with surgery. Conclusion: We recognized that oriental-western medicine integrative care after gynecology surgery has significant effect.

• The Journal of Korean Medicine
• /
• v.30 no.6
• /
• pp.112-117
• /
• 2009

Objective: Rhus verniciflua Stokes (RVS) has anticancer effect confirmed by preclinical studies and historical records. We thus tried to evaluate retrospectively the effect of RVS as a complementary medicine for patients with advanced non-small-cell lung cancer (NSCLC) showing refractory to conventional chemotherapy. Patients and Methods: From June 1, 2006 to June 30, 2007, patients with advanced NSCLC who received both the standardized RVS extract and a standard course of second or more line therapy such as pemetrexed ($Alimta^{(R)}$), erlotinib ($Tarceva^{(R)}$), and gefitinib ($Iressa^{(R)}$) were checked. A total of 13 patients were eligible for the final analysis after fulfilling inclusion/exclusion criteria. Time to progression (TTP) of these patients treated with the standardized RVS extract was checked in the aftercare period. Results: Patients received RVS treatment for a median period of 296 (range 84-698) days. The median TTP was 220.5 (range 36-489) days, and three patients (23.1%) had TTP values of 15 more months. No significant side effects from RVS treatment have been observed. Conclusion: The standardized RVS extract might have synergetic effects by assisting apoptosis in advanced NSCLC with concurrent standard therapy agents, since it prolonged TTP without significant adverse effects. This study suggests that the standardized RVS extract is beneficial to patients with chemotherapy-refractory NSCLC. Further clinical trials and preclinical studies are necessary to determine the efficacy and safety of the standardized RVS extract in NSCLC.

• Journal of Pharmacopuncture
• /
• v.26 no.1
• /
• pp.94-98
• /
• 2023

A forty-three-year-old male patient was diagnosed with an acute abscess in the dorsum of the right hand. On the 5th day of conventional pharmacological therapy the patient was still suffering, and was referred to the Outpatient department (OPD) to evacuate and drain the abscess and treat the edema around the area with Hijama (wet cupping therapy, WCT). The hand abscess was successfully cured within a week using an integrative approach of wet cupping therapy together with conventional drug therapy.

• Journal of Korean Traditional Oncology
• /
• v.11 no.1
• /
• pp.1-21
• /
• 2006

This study was undertaken to evaluate safety and antitumor activity of Nexia, a processed extract of Rhus verniciflua STOKES by heating according to Korean patent 0504160 through toxicology, cancer research and clinical application. Nexia did not exhibit any toxicological symptoms through 13 week continuous treatment, dosage accumulation study and anaphylaxis response. The lifespan of four patients with acute lymphocytic leukemia under complete remission were 110, 83, 97, and 86 months after treatment of Nexia, respectively. These data suggest that Nexia, a processed extract by removing allergen from Rhus verniciflua STOKES, may have safety and antitumor activity and also still need continuous study on its mechanism and clinical trial.

• BMB Reports
• /
• v.55 no.11
• /
• pp.553-558
• /
• 2022

Hepatocellular carcinoma (HCC) is dangerous cancer that often evades early detection because it is asymptomatic and an effective detection method is lacking. For people with chronic liver inflammation who are at high risk of developing HCC, a sensitive detection method for HCC is needed. In a meta-analysis of The Cancer Genome Atlas pan-cancer methylation database, we identified a CpG island in the USP44 promoter that is methylated specifically in HCC. We developed methylation-sensitive high-resolution melting (MS-HRM) analysis to measure the methylation levels of the USP promoter in cell-free DNA isolated from patients. Our MS-HRM assay correctly identified 40% of patients with early-stage HCC, whereas the α-fetoprotein test, which is currently used to detect HCC, correctly identified only 25% of early-stage HCC patients. These results demonstrate that USP44 MS-HRM analysis is suitable for HCC surveillance.

• The Journal of Churna Manual Medicine for Spine and Nerves
• /
• v.12 no.1
• /
• pp.71-81
• /
• 2017

Objectives : It is important to develop a new Chuna manual therapy as a representative of Chuna manual therapy technique at the time of KSCMM's (Korean Society of Chuna manual medicine) joining a $F{\acute{e}}d{\acute{e}}ration$ Internationale de $M{\acute{e}}decine$ Manuelle (FIMM). Therefore, Sunu manual therapy (SMT) will be introduced as a purely new Chuna manual therapy. Main subject : Sunu manual therapy (SMT) was discovered about two decade ago by a Korean Medicine doctor who wanted to develop a new manual therapy to treat a internal disease. It is very important to make the best use of four powers such as a compression force, a torsion force, a bending force, a tension force using a resonance principle and to experience a feeling of spine axis. SMT is different from Chiropractic technique and Osteopathy technique, in that SMT could treat so many disease using only one technique, but other manual therapy could utilize so many technique to treat only one disease. Discussion : Because SMT utilize a power of a moving in silience, it will take several years to totally master a SMT which will make a patient and a doctor experience a feeling of spine axis. As a feeling of spine axis is deeper, a nerve could be excited and treated by a SMT. Also as a feeling of spine axis is shallower, a muscle could be excied and treated by a SMT. Conclusions : SMT could be classed as a craniosacral chuna therapy or visceral chuna therapy to treat a internal disease considering SMT's action and purpose.

• Journal of The Korean Society of Integrative Medicine
• /
• v.9 no.3
• /
• pp.185-192
• /
• 2021

Purpose : Our study aimed to compare the effectiveness of low-level laser therapy (LLLT) and light-emitting diode therapy (LEDT) for chronic pain intensity reduction and body temperature increase in older adults with chronic pain. Methods : Overall, 144 of 332 participants' records were used in this retrospective chart review. The study was conducted at a private health center in Busan city and the integrative medical center of a tertiary care hospital in Daegu city, South Korea. Patients experiencing chronic pain for over 6 months were assigned to either the LLLT or LEDT group. Both groups underwent 16 sessions of phototherapy held twice a week for 8 weeks, with each session lasting 60 minutes. The primary outcomes for both groups were the mean visual analogue scale (VAS) scores and body temperatures in both groups. The secondary outcome was the correlation between changes in body temperature and pain intensity. Measurements were recorded at the baseline and at each follow-up session. Results : A decrease in pain intensity and an increase in body temperature (p<.001) were observed in both groups. There was a significant difference in the VAS scores and temperature changes between the groups (p<.001). Odditionally, there were significant differences in the patterns of change in the VAS score and body temperature between the groups as the sessions progressed (p<.01), and a strong inverse correlation between body temperature and pain intensity changes were observed (p<.01). Conclusion : The use of photobiomodulation therapy at a specific wavelength may improve pain severity and simultaneously increase the body temperature among elderly people with chronic pain.

• Journal of Korean Traditional Oncology
• /
• v.19 no.1
• /
• pp.43-51
• /
• 2014

This report is aimed to investigate the effect of Integrative Medicine Therapy (IMT) in treating breast cancer metastasized to several portion. A 55-year-old woman who was diagnosed breast cancer and treated by breast conservation surgery (BCS) IN 2002. (pT2M0N0), adjuvant chemotherapy and radiotherapy till Jan. in 2013. But cancer had metastasized to sacrum (2009), liver (2012) and ribs (2013). Finally cause of several side effects of Xeloda(neuralgia and vommiting), she gave up to be treated by Xeloda and started to receive IMT including Abnoba Viscum, Vitamin C therapy Xeloda again, Korean herbal medicine and pharmacopuncture from Jul. in 2013. The effect was evaluated with Positron Emission Tomography and Computed Tomography (PET-CT) and Abdomen Computed Tomography (CT). The metastatic tumor in liver was disappeared and cancers to ribs, their size decreased after 12 months and pain of sacrum maintained VAS 2 continually. These results suggest that IMT is a therapeutic method to treat metastatic tumor originated from breast cancer.